Skip to main content
    P

    Precipio Inc (PRPO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $19.96
    -2.17 (-9.81%)

    Market Cap: $39.68M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Precipio Inc (PRPO) Earnings: Report Dates and Results

    Updated Aug 14, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Precipio (PRPO) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Precipio reported EPS of -$0.12. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    30%(7/23)
    Avg Surprise
    -66.13%

    Next Report

    PRPO has an expected report date of Mar 29, 2027.

    PRPO Earnings Call

    The latest PRPO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 24 quarters below that had an estimate, PRPO beat 8, missed 14 and matched 2. Revenue for the quarter ended Jun 30, 2026 was $7.02M, up 24.2% from $5.65M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.12N/AN/AN/AN/A-340.0%N/AN/AAug 14, 2026$7.02M
    Mar 31, 2026-$0.81N/AN/AN/AN/AN/AN/AN/AMay 19, 2026$6.71M
    Sep 30, 2025-$0.05N/AN/AN/AN/AN/AN/AN/ANov 14, 2025$6.77M
    Jun 30, 2025$0.05N/AN/AN/AN/AN/AN/AN/AAug 13, 2025$5.65M
    Mar 31, 2025-$0.59N/AN/AN/AN/A-190.3%N/AN/AMay 14, 2025$4.93M
    Dec 31, 2024-$0.24$0.74N/A-133.03%MissN/AN/AN/AMar 27, 2025$5.45M
    Sep 30, 2024-$0.42N/AN/AN/AN/AN/AN/AN/ANov 6, 2024$5.21M
    Jun 30, 2024-$0.83N/AN/AN/AN/AN/AN/AN/AAug 13, 2024$4.44M
    Mar 31, 2024$0.65N/AN/AN/AN/AN/AN/A0 up, 1 downMay 14, 2024$3.43M
    Sep 30, 2023-$1.04-$1.40N/A+25.71%BeatN/A11 up, 0 downNov 13, 2023$4.52M
    Jun 30, 2023-$1.80-$2.00-$2.00 - -$2.00+10.00%BeatN/A10 up, 0 downAug 11, 2023$3.53M
    Mar 31, 2023-$2.60-$2.60-$2.60 - -$2.600.00%In lineN/A10 up, 0 downMay 12, 2023$2.82M
    Dec 31, 2022-$0.10-$0.14-$0.14 - -$0.14+28.57%BeatN/A10 up, 0 downMar 30, 2023$2.39M
    Sep 30, 2022-$2.80-$0.80N/A-250.00%MissN/AN/AN/ANov 10, 2022$2.21M
    Jun 30, 2022-$1.80-$1.00N/A-80.00%MissN/AN/A0 up, 0 downAug 11, 2022$2.36M
    Mar 31, 2022-$4.00-$1.00N/A-300.00%MissN/AN/A0 up, 0 downMay 11, 2022$2.45M
    Dec 31, 2021-$0.09-$0.08-$0.08 - -$0.08-12.50%MissN/A10 up, 0 downMar 30, 2022$2.44M
    Sep 30, 2021-$1.60-$2.00N/A+20.00%BeatN/AN/A0 up, 0 downNov 12, 2021$2.25M
    Jun 30, 2021-$2.80-$2.00N/A-40.00%MissN/AN/AN/AAug 12, 2021$2.34M
    Mar 31, 2021-$1.60-$2.00-$2.00 - -$2.00+20.00%BeatN/A1N/AMay 14, 2021$1.82M
    Dec 31, 2020-$0.11-$0.09N/A-22.22%MissN/AN/AN/AMar 29, 2021$1.94M
    Sep 30, 2020-$4.20-$4.00N/A-5.00%MissN/AN/AN/ANov 13, 2020$4.10M
    Jun 30, 2020-$4.00-$4.00-$4.00 - -$4.000.00%In lineN/A1N/AAug 13, 2020$1.31M
    Mar 31, 2020-$12.72-$3.60-$3.60 - -$3.60-253.33%MissN/A1N/AMay 14, 2020$1.22M
    Dec 31, 2019-$0.48-$0.17-$0.25 - -$0.10-182.35%MissN/A2N/AMar 27, 2020$688000
    Sep 30, 2019-$6.20-$7.80-$7.80 - -$7.80+20.51%BeatN/A1N/ANov 13, 2019$784000
    Jun 30, 2019-$21.00-$7.40-$7.40 - -$7.40-183.78%MissN/A1N/AAug 9, 2019$942000
    Mar 31, 2019-$0.48-$0.43N/A-11.63%MissN/AN/AN/AApr 16, 2019$713000
    Dec 31, 2018-$0.23-$0.67N/A+65.67%BeatN/AN/AN/AFeb 27, 2019$685000
    Sep 30, 2018-$0.17$0.57N/A-129.82%MissN/AN/AN/ANov 19, 2018$650000
    Jun 30, 2018-$0.15$1.93N/A-107.77%MissN/AN/AN/AAug 17, 2018$817000
    Mar 31, 2018-$0.47N/AN/AN/AN/AN/AN/AN/AApr 13, 2018$712000
    Dec 31, 2017-$1.23N/AN/AN/AN/AN/AN/AN/AFeb 28, 2018$1.25M
    Sep 30, 2017-$1.36N/AN/AN/AN/AN/AN/AN/ANov 20, 2017$270000
    Jun 30, 2017-$15.35N/AN/AN/AN/AN/AN/AN/AAug 21, 2017$260000
    Mar 31, 2017-$1.38N/AN/AN/AN/A-100.9%N/AN/AApr 13, 2017N/A
    Dec 31, 2016-$31.50N/AN/AN/AN/A-8850.0%N/AN/AMar 15, 2017$618000
    Sep 30, 2016Not reportedN/AN/AN/ANot reportedN/AN/AN/ANov 14, 2016$365000
    Jun 30, 2016Not reportedN/AN/AN/ANot reportedN/AN/AN/AAug 12, 2016$504000
    Mar 31, 2016$162.00-$76.50N/A+311.76%BeatN/AN/AN/AApr 14, 2016$236000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2024 was -$6.29, after -$8.70 in the fiscal year ended Dec 31, 2022. It was -$724.50 for the year ended Dec 31, 2013, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2024-$6.29N/A
    Dec 31, 2022-$8.70N/A
    Dec 31, 2021-$6.09N/A
    Dec 31, 2020-$21.03N/A
    Dec 31, 2019-$28.16N/A
    Dec 31, 2018-$1.02N/A
    Dec 31, 2017-$19.32-114.8%
    Dec 31, 2016$130.50N/A
    Dec 31, 2015-$1,115.64N/A
    Dec 31, 2013-$724.50N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,1068
    2026Q2Jun 30, 20262,9403
    2026Q1Mar 31, 20264,1414
    2025Q2Jun 30, 20252,3902
    2025Q1Mar 31, 20253,1752
    2024Q3Sep 30, 20241,7412
    2024Q2Jun 30, 20241,8782

    2026Q3 Earnings Call

    Opening remarks

    Ilan Danieli CEO Good afternoon, everyone, and thank you for joining us. Before we jump into a review of the results for Q3 2026 and share several thoughts for 2027, I thought that as we come to the end of another successful year, it might be helpful to add another member of the management team to these calls. I'd like to introduce my co-founder and Precipio's Chief Operating Officer, Zaki Sabet. Along with Dr. Ayman Mohamed, the three of us started Precipio in 2011, and we've been inseparable since. Prior to founding Precipio, Zaki spent his career in the diagnostics industry. While at college, Zaki worked as an accessioner during the night shift in a lab in New Jersey. Over the years, he moved up through the ranks from lab technician to supervisor and eventually managed the entire laboratory. Bringing his in-depth expertise, Zaki was responsible for building what is today, to the best of our knowledge, at our size, one of the few profitable hematopathology laboratories in the country. At Precipio, Zaki oversees all company operations, including both our clinical laboratory and operations for the products division, including manufacturing and supply chain. Today, Zaki will be joining me in sharing some remarks, and then we'll also be available to answer questions during the Q&A section. As this is our last scheduled shareholder call of 2026, I'd like to put these results in the context of the progress we've made over the past couple of years and explain how that progress sets the stage for 2027. In 2025, our focus was on getting the company to a cash-flow-positive position. We'd gone through several dilutive financings and decided that it was time for the company to stand on its own two feet and become financially independent. So we set our sights on reaching cash flow positive through a combination of revenue growth alongside significant operational efficiency improvements. And at the end of 2025, we were there. Our company was cash flow positive, no longer dependent on outside capital in order to survive. And for the first time, we were able to respond to the calls from the various investment banks and hedge funds looking to provide capital to Precipio with a polite but clear, 'No, thank you.' I can tell you, as the person responsible for raising money to keep the lights on for 15 years, that was a wonderful moment. The second goal in 2025 was to determine if the products we created and that were used in our own lab would be of real value to other laboratories. We carefully explored this market by identifying target customers in several segments, which would serve as an indicator of market interest.

    Frequently Asked Questions About PRPO

    When is Precipio's next earnings date?

    Precipio's next earnings report is expected for Mar 29, 2027.

    How often does PRPO beat earnings estimates?

    Precipio beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -87.34%.